Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer.

Internal medicine (Tokyo, Japan) - 1 Jan 2021

Oyama Baku, Morikawa Kei, Sakaguchi Tadashi, Tsunoda Akihito, Kida Hirotaka, Inoue Takeo, Mineshita Masamichi

Abstract excerpt

An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis showed an increased inflammatory response. Afatinib treatment was discontinued on the same day. On Day 26, the patient displayed blepharedema and multiple irregular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Afatinib

Share to Aged, 80 and over

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Pharmaceutical Preparations

Source

Open in PubMed Open full text

Identifiers

PMID: 33518612
DOI: 10.2169/internalmedicine.4237-19
PMCID: PMC7925278

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer.PMID 33518612Read ↗

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity Read ↗

Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.Semantic proximity Read ↗

Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.Semantic proximity Read ↗

Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.Semantic proximity Read ↗

A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients.Semantic proximity Read ↗

[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].Semantic proximity Read ↗

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.Semantic proximity Read ↗

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.Semantic proximity Read ↗

Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.Semantic proximity Read ↗

Pulsed Azithromycin for the Treatment of Dacomitinib Induced Skin Toxicity in Patient with Tetracycline Intolerance – A Case ReportSemantic proximity Read ↗

Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.Semantic proximity Read ↗

Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.